Lower Limb Ulcer
Patients suffering from diabetes may develop complications of peripheral ischemia or neuropathy, which may lead to “lower limb ulcer” caused by difficulty of wound healing. It is estimated that about 2% of diabetes patient may develop Lower Limb Ulcer in their lifetime. Some severe ones may even lead to amputation.
TWB-103 has exhibited therapeutic potential to lower limb ulcer in several pre-clinical studies!
Transwell Biotech is currently preparing for the Phase I/II clinical trial in treating lower limb ulcer. It is expected to file IND at mid-2018.
Figure 1: The porcine model indicates that TWB-103 can promote linkage between dermis and epidermis.
Figure 2: TWB-103 promotes granulation in wound healing in diabetic porcine model.